ERBB2 and breast adenocarcinoma: Support for this consideration in based on the observation that there was a simple dose effect for gemcitabine-(C4-amide)-[anti-HER2/neu], and because mammary adenocarcinoma (SKBr-3) survivability was very similar when challenged with gemcibatine-(C5-methylcarbamate)-[anti-HER2/neu] [22] or gemcitabine-(C4-amide)-[anti-HER2/neu] [23] at 182-hours compared to gemcitabine at 72-hours, and increased dramatically for gemcitabine when the incubation period was extended to 182-hours (Figures 4,7 and 8) [22,23].